EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target | Zendy

Keri Toner | Zendy; Catherine M. Bollard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target

Author(s) -

Keri Toner,

Catherine M. Bollard

Publication year - 2021

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2020005466

Subject(s) - lymphoproliferative disorders , epstein–barr virus , immunology , lymphoproliferative disease , virus , immune system , lymphoma , disease , medicine , virology , biology , cancer research , pathology

Epstein-Barr virus (EBV) is a ubiquitous human tumor virus, which contributes to the development of lymphoproliferative disease, most notably in patients with impaired immunity. EBV-associated lymphoproliferation is characterized by expression of latent EBV proteins and ranges in severity from a relatively benign proliferative response to aggressive malignant lymphomas. The presence of EBV can also serve as a unique target for directed therapies for the treatment of EBV lymphoproliferative diseases, including T cell–based immune therapies. In this review, we describe the EBV-associated lymphoproliferative diseases and particularly focus on the therapies that target EBV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research